<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3953">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01309646</url>
  </required_header>
  <id_info>
    <org_study_id>114260</org_study_id>
    <nct_id>NCT01309646</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine</brief_title>
  <official_title>Immunogenicity and Safety of GlaxoSmithKline Biologicals' DTPa-IPV/Hib (Infanrix™-IPV+Hib) Vaccine in Healthy Korean Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety and immunogenicity of Infanrix™-IPV+Hib
      vaccine when administered as a primary vaccination course to healthy Korean infants at 2, 4
      and 6 months of age.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Number of Seroprotected Subjects for Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibodies.</measure>
    <time_frame>At Month 0 and Month 5</time_frame>
    <safety_issue>No</safety_issue>
    <description>A seroprotected subject was defined as a vaccinated subject who had an anti-D and anti-T antibody concentration greater to or above (≥) 0.1 international units per milliliter (IU/mL). The Month 5 results are the primary outcome variables.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Seropositive Subjects for Anti-pertactin (Anti-PRN) Antibodies.</measure>
    <time_frame>At Month 0 and Month 5</time_frame>
    <safety_issue>No</safety_issue>
    <description>A seropositive subjects was defined as a vaccinated subjects who had an anti-PRN antibody concentration ≥ 5 ELISA units per milliliter (EL.U/mL). The Month 5 results are the primary outcome variables.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Seroprotected Subjects for Anti-polyribosyl-ribitol-phosphate (Anti-PRP) Antibodies.</measure>
    <time_frame>At Month 0 and Month 5</time_frame>
    <safety_issue>No</safety_issue>
    <description>A seroprotected subject was defined as a vaccinated subject who had an anti-PRP antibody concentration ≥ 0.15 micrograms per milliliter (µg/mL). The Month 5 results are the primary outcome variables.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Seroprotected Subjects Anti-poliovirus (Anti-polio) Types 1, 2 and 3.</measure>
    <time_frame>At Month 0 and Month 5</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentrations of Anti-PT Antibodies.</measure>
    <time_frame>At Month 0 and Month 5</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentrations of Anti-FHA Antibodies.</measure>
    <time_frame>At Month 0 and Month 5</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Solicited Local Symptoms.</measure>
    <time_frame>During the 4-day (Days 0-3) follow-up period after any vaccination with Infanrix™-IPV+Hib or Infanrix™ IPV + Hiberix™</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed solicited local symptoms were pain, redness and swelling at the injection site. Any = incidence of a particular symptom regardless of intensity grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Solicited General Symptoms.</measure>
    <time_frame>During the 4-day (Days 0-3) follow-up period after any vaccination with Infanrix™-IPV+Hib or Infanrix™ IPV + Hiberix™</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed solicited general symptoms were drowsiness, irritability/fussiness, loss of appetite and fever [defined as tympanic temperature ≥ 37.5 degrees Celsius (°C)]. Any = incidence of a particular symptom regardless of intensity grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Unsolicited Adverse Events (AEs).</measure>
    <time_frame>During the 31-day (Days 0-30) follow-up period after any vaccination with Infanrix™-IPV+Hib or Infanrix™ IPV + Hiberix™</time_frame>
    <safety_issue>No</safety_issue>
    <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = any unsolicited AE regardless of intensity or relationship to vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Serious Adverse Events (SAEs).</measure>
    <time_frame>During the entire study period (from Month 0 to Month 5 ½)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations for Anti-D and Anti-T Antibodies.</measure>
    <time_frame>At Month 0 and Month 5</time_frame>
    <safety_issue>No</safety_issue>
    <description>Concentrations were expressed as geometric mean concentrations (GMCs). The seroprotection cut-off of the assay was 0.1 IU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of Anti-PRN Antibodies.</measure>
    <time_frame>At Month 0 and Month 5</time_frame>
    <safety_issue>No</safety_issue>
    <description>Concentrations were expressed as geometric mean concentrations (GMCs). The seropositivity cut-off of the assay was 5 EL.U/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of Anti-PRP Antibodies.</measure>
    <time_frame>At Month 0 and Month 5</time_frame>
    <safety_issue>No</safety_issue>
    <description>Concentrations were expressed as geometric mean concentrations (GMCs). The seroprotection cut-off of the assay was 0.15 µg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With a Vaccine Response.</measure>
    <time_frame>At Month 5</time_frame>
    <safety_issue>No</safety_issue>
    <description>Vaccine response was defined as antibody concentration ≥ 5 EL.U/mL at post vaccination, for initially seronegative subjects, and at least maintenance of antibody concentration from pre to post-vaccination (i.e. antibody concentration at post vaccination ≥ 1 fold the pre-vaccination antibody concentration), for initially seropositive subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations for Anti-polio Types 1, 2 and 3.</measure>
    <time_frame>At Month 0 and Month 5</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seropositive Subjects for Anti-PT Antibodies.</measure>
    <time_frame>At Month 0 and Month 5</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seropositive Subjects for Anti-FHA Antibodies.</measure>
    <time_frame>At Month 0 and Month 5</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">454</enrollment>
  <condition>Poliomyelitis</condition>
  <condition>Haemophilus Influenzae Type b Disease</condition>
  <condition>Diphtheria</condition>
  <condition>Pertussis</condition>
  <condition>Tetanus</condition>
  <arm_group>
    <arm_group_label>Infanrix-IPV+Hib Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™-IPV+Hib at 2, 4 and 6 months of age, 3 doses of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™-IPV+Hib was administered intramuscularly in the right thigh, the Synflorix™ vaccine was administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infanrix IPV Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™ IPV and Hiberix™ co-administered at separate injection sites at 2, 4 and 6 months of age, 3 dose of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™ IPV was administered intramuscularly in the right thigh, the Synflorix™ and Hiberix™ vaccines were administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infanrix™-IPV+Hib</intervention_name>
    <description>Intramuscular, 3 doses</description>
    <arm_group_label>Infanrix-IPV+Hib Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infanrix™ IPV</intervention_name>
    <description>Intramuscular, 3 doses</description>
    <arm_group_label>Infanrix IPV Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hiberix™</intervention_name>
    <description>Intramuscular, 3 doses</description>
    <arm_group_label>Infanrix IPV Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Synflorix™</intervention_name>
    <description>Intramuscular, 3 doses</description>
    <arm_group_label>Infanrix-IPV+Hib Group</arm_group_label>
    <arm_group_label>Infanrix IPV Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rotarix™</intervention_name>
    <description>Oral, 2 doses</description>
    <arm_group_label>Infanrix-IPV+Hib Group</arm_group_label>
    <arm_group_label>Infanrix IPV Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A male or female between, and including, 42 and 69 days of age at the time of the
             first vaccination.

          -  Born after a gestation period of 37 to 42 weeks inclusive.

          -  Subjects who the investigator believes that parent(s)/Legally Acceptable
             Representative(s) can and will comply with the requirements of the protocol.

          -  Written informed consent obtained from the parent(s)/ Legally Acceptable
             Representative(s) of the subject.

          -  Healthy subjects as established by medical history and clinical examination before
             entering into the study.

        Exclusion Criteria:

          -  Child in care.

          -  Use of any investigational or non-registered product other than the study vaccine(s)
             within 30 days preceding the first dose, or planned use during the study period.

          -  Chronic administration of immunosuppressants or other immune-modifying drugs since
             birth.

          -  Administration of a vaccine not foreseen by the study protocol, within 30 days prior
             to the first study visit, with the exception of hepatitis B and Bacillus
             Calmette-Guérin vaccination; or planned administration during the study period, with
             the exception of hepatitis B and influenza vaccines, which will be allowed at least 7
             days before or 30 days after the administration of the DTPa vaccine.

          -  Concurrently participating in another clinical study, at any time during the study
             period, in which the subject has been or will be exposed to an investigational or a
             non-investigational product.

          -  Evidence of previous or intercurrent diphtheria, tetanus, pertussis, poliomyelitis
             and Hib vaccination or disease.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination.

          -  Family history of congenital or hereditary immunodeficiency.

          -  History of any reaction or hypersensitivity likely to be exacerbated by any component
             of the vaccine(s).

          -  Major congenital defects or serious chronic illness.

          -  History of any neurological disorders or seizures.

          -  Administration of immunoglobulins and/or any blood products since birth or planned
             administration during the study period.

          -  Acute disease and/or fever at the time of enrolment.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>42 Days</minimum_age>
    <maximum_age>69 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Daegu</city>
        <zip>700-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Goyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>GyeongSangNam-do</city>
        <zip>641-560</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Iksan</city>
        <zip>570-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jeonju Jeonbuk</city>
        <zip>561-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seongnam-si</city>
        <zip>463-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>139-706</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Suwon City, Gyeonggi-do</city>
        <zip>442-723</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Uijeongbu, Gyeonggi-do</city>
        <zip>480-717</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wonju-si Kangwon-do</city>
        <zip>220-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>April 18, 2013</lastchanged_date>
  <firstreceived_date>February 24, 2011</firstreceived_date>
  <firstreceived_results_date>February 21, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary vaccination</keyword>
  <keyword>combination vaccine</keyword>
  <keyword>South Korea</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Poliomyelitis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Infanrix-IPV+Hib Group</title>
          <description>Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™-IPV+Hib at 2, 4 and 6 months of age, 3 doses of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™-IPV+Hib was administered intramuscularly in the right thigh, the Synflorix™ vaccine was administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.</description>
        </group>
        <group group_id="P2">
          <title>Infanrix IPV Group</title>
          <description>Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™ IPV and Hiberix™ co-administered at separate injection sites at 2, 4 and 6 months of age, 3 dose of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™ IPV was administered intramuscularly in the right thigh, the Synflorix™ and Hiberix™ vaccines were administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="226"/>
                <participants group_id="P2" count="228"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="224"/>
                <participants group_id="P2" count="227"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Infanrix-IPV+Hib Group</title>
          <description>Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™-IPV+Hib at 2, 4 and 6 months of age, 3 doses of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™-IPV+Hib was administered intramuscularly in the right thigh, the Synflorix™ vaccine was administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.</description>
        </group>
        <group group_id="B2">
          <title>Infanrix IPV Group</title>
          <description>Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™ IPV and Hiberix™ co-administered at separate injection sites at 2, 4 and 6 months of age, 3 dose of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™ IPV was administered intramuscularly in the right thigh, the Synflorix™ and Hiberix™ vaccines were administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="226"/>
                <measurement group_id="B2" value="228"/>
                <measurement group_id="B3" value="454"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="8.8" spread="1.10"/>
                <measurement group_id="B2" value="8.8" spread="1.09"/>
                <measurement group_id="B3" value="8.8" spread="1.09"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Subjects</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="98"/>
                <measurement group_id="B2" value="116"/>
                <measurement group_id="B3" value="214"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="128"/>
                <measurement group_id="B2" value="112"/>
                <measurement group_id="B3" value="240"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Solicited Local Symptoms.</title>
        <description>Assessed solicited local symptoms were pain, redness and swelling at the injection site. Any = incidence of a particular symptom regardless of intensity grade.</description>
        <time_frame>During the 4-day (Days 0-3) follow-up period after any vaccination with Infanrix™-IPV+Hib or Infanrix™ IPV + Hiberix™</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects with at least one vaccine administration documented and with the symptom sheet completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix-IPV+Hib Group</title>
            <description>Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™-IPV+Hib at 2, 4 and 6 months of age, 3 doses of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™-IPV+Hib was administered intramuscularly in the right thigh, the Synflorix™ vaccine was administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix IPV Group</title>
            <description>Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™ IPV and Hiberix™ co-administered at separate injection sites at 2, 4 and 6 months of age, 3 dose of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™ IPV was administered intramuscularly in the right thigh, the Synflorix™ and Hiberix™ vaccines were administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="224"/>
                  <measurement group_id="O2" value="227"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Any Solicited Local Symptoms.</title>
            <description>Assessed solicited local symptoms were pain, redness and swelling at the injection site. Any = incidence of a particular symptom regardless of intensity grade.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="143"/>
                  <measurement group_id="O2" value="146"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Redness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="177"/>
                  <measurement group_id="O2" value="167"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Swelling</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="130"/>
                  <measurement group_id="O2" value="121"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Solicited General Symptoms.</title>
        <description>Assessed solicited general symptoms were drowsiness, irritability/fussiness, loss of appetite and fever [defined as tympanic temperature ≥ 37.5 degrees Celsius (°C)]. Any = incidence of a particular symptom regardless of intensity grade.</description>
        <time_frame>During the 4-day (Days 0-3) follow-up period after any vaccination with Infanrix™-IPV+Hib or Infanrix™ IPV + Hiberix™</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects with at least one vaccine administration documented and with the symptom sheet completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix-IPV+Hib Group</title>
            <description>Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™-IPV+Hib at 2, 4 and 6 months of age, 3 doses of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™-IPV+Hib was administered intramuscularly in the right thigh, the Synflorix™ vaccine was administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix IPV Group</title>
            <description>Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™ IPV and Hiberix™ co-administered at separate injection sites at 2, 4 and 6 months of age, 3 dose of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™ IPV was administered intramuscularly in the right thigh, the Synflorix™ and Hiberix™ vaccines were administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="224"/>
                  <measurement group_id="O2" value="227"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Any Solicited General Symptoms.</title>
            <description>Assessed solicited general symptoms were drowsiness, irritability/fussiness, loss of appetite and fever [defined as tympanic temperature ≥ 37.5 degrees Celsius (°C)]. Any = incidence of a particular symptom regardless of intensity grade.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any Drowsiness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="153"/>
                  <measurement group_id="O2" value="147"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Irritability/Fussiness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="181"/>
                  <measurement group_id="O2" value="182"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Loss of appetite</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="120"/>
                  <measurement group_id="O2" value="103"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Temperature ≥ 37.5°C</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="83"/>
                  <measurement group_id="O2" value="81"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Unsolicited Adverse Events (AEs).</title>
        <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = any unsolicited AE regardless of intensity or relationship to vaccination.</description>
        <time_frame>During the 31-day (Days 0-30) follow-up period after any vaccination with Infanrix™-IPV+Hib or Infanrix™ IPV + Hiberix™</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects with at least one vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix-IPV+Hib Group</title>
            <description>Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™-IPV+Hib at 2, 4 and 6 months of age, 3 doses of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™-IPV+Hib was administered intramuscularly in the right thigh, the Synflorix™ vaccine was administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix IPV Group</title>
            <description>Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™ IPV and Hiberix™ co-administered at separate injection sites at 2, 4 and 6 months of age, 3 dose of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™ IPV was administered intramuscularly in the right thigh, the Synflorix™ and Hiberix™ vaccines were administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="224"/>
                  <measurement group_id="O2" value="227"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Any Unsolicited Adverse Events (AEs).</title>
            <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = any unsolicited AE regardless of intensity or relationship to vaccination.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="131"/>
                  <measurement group_id="O2" value="123"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Serious Adverse Events (SAEs).</title>
        <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
        <time_frame>During the entire study period (from Month 0 to Month 5 ½)</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects with at least one vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix-IPV+Hib Group</title>
            <description>Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™-IPV+Hib at 2, 4 and 6 months of age, 3 doses of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™-IPV+Hib was administered intramuscularly in the right thigh, the Synflorix™ vaccine was administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix IPV Group</title>
            <description>Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™ IPV and Hiberix™ co-administered at separate injection sites at 2, 4 and 6 months of age, 3 dose of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™ IPV was administered intramuscularly in the right thigh, the Synflorix™ and Hiberix™ vaccines were administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="224"/>
                  <measurement group_id="O2" value="227"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Any Serious Adverse Events (SAEs).</title>
            <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="21"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroprotected Subjects for Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibodies.</title>
        <description>A seroprotected subject was defined as a vaccinated subject who had an anti-D and anti-T antibody concentration greater to or above (≥) 0.1 international units per milliliter (IU/mL). The Month 5 results are the primary outcome variables.</description>
        <time_frame>At Month 0 and Month 5</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, which included all evaluable subjects who received one dose of either study vaccine according to their random assignment, for whom administration site of study vaccine was known and for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix-IPV+Hib Group</title>
            <description>Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™-IPV+Hib at 2, 4 and 6 months of age, 3 doses of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™-IPV+Hib was administered intramuscularly in the right thigh, the Synflorix™ vaccine was administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix IPV Group</title>
            <description>Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™ IPV and Hiberix™ co-administered at separate injection sites at 2, 4 and 6 months of age, 3 dose of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™ IPV was administered intramuscularly in the right thigh, the Synflorix™ and Hiberix™ vaccines were administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="213"/>
                  <measurement group_id="O2" value="217"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Seroprotected Subjects for Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibodies.</title>
            <description>A seroprotected subject was defined as a vaccinated subject who had an anti-D and anti-T antibody concentration greater to or above (≥) 0.1 international units per milliliter (IU/mL). The Month 5 results are the primary outcome variables.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Anti-D at Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                  <measurement group_id="O2" value="30"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-D at Month 5</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="213"/>
                  <measurement group_id="O2" value="217"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-T at Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="64"/>
                  <measurement group_id="O2" value="76"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-T at Month 5</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="213"/>
                  <measurement group_id="O2" value="217"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Seropositive Subjects for Anti-pertactin (Anti-PRN) Antibodies.</title>
        <description>A seropositive subjects was defined as a vaccinated subjects who had an anti-PRN antibody concentration ≥ 5 ELISA units per milliliter (EL.U/mL). The Month 5 results are the primary outcome variables.</description>
        <time_frame>At Month 0 and Month 5</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, which included all evaluable subjects who received one dose of either study vaccine according to their random assignment, for whom administration site of study vaccine was known and for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix-IPV+Hib Group</title>
            <description>Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™-IPV+Hib at 2, 4 and 6 months of age, 3 doses of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™-IPV+Hib was administered intramuscularly in the right thigh, the Synflorix™ vaccine was administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix IPV Group</title>
            <description>Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™ IPV and Hiberix™ co-administered at separate injection sites at 2, 4 and 6 months of age, 3 dose of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™ IPV was administered intramuscularly in the right thigh, the Synflorix™ and Hiberix™ vaccines were administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="213"/>
                  <measurement group_id="O2" value="217"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Seropositive Subjects for Anti-pertactin (Anti-PRN) Antibodies.</title>
            <description>A seropositive subjects was defined as a vaccinated subjects who had an anti-PRN antibody concentration ≥ 5 ELISA units per milliliter (EL.U/mL). The Month 5 results are the primary outcome variables.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Anti-PRN at Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="30"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-PRN at Month 5</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="213"/>
                  <measurement group_id="O2" value="217"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroprotected Subjects for Anti-polyribosyl-ribitol-phosphate (Anti-PRP) Antibodies.</title>
        <description>A seroprotected subject was defined as a vaccinated subject who had an anti-PRP antibody concentration ≥ 0.15 micrograms per milliliter (µg/mL). The Month 5 results are the primary outcome variables.</description>
        <time_frame>At Month 0 and Month 5</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, which included all evaluable subjects who received one dose of either study vaccine according to their random assignment, for whom administration site of study vaccine was known and for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix-IPV+Hib Group</title>
            <description>Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™-IPV+Hib at 2, 4 and 6 months of age, 3 doses of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™-IPV+Hib was administered intramuscularly in the right thigh, the Synflorix™ vaccine was administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix IPV Group</title>
            <description>Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™ IPV and Hiberix™ co-administered at separate injection sites at 2, 4 and 6 months of age, 3 dose of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™ IPV was administered intramuscularly in the right thigh, the Synflorix™ and Hiberix™ vaccines were administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="213"/>
                  <measurement group_id="O2" value="217"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Seroprotected Subjects for Anti-polyribosyl-ribitol-phosphate (Anti-PRP) Antibodies.</title>
            <description>A seroprotected subject was defined as a vaccinated subject who had an anti-PRP antibody concentration ≥ 0.15 micrograms per milliliter (µg/mL). The Month 5 results are the primary outcome variables.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Anti-PRP at Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="91"/>
                  <measurement group_id="O2" value="109"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-PRP at Month 5</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="213"/>
                  <measurement group_id="O2" value="217"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroprotected Subjects Anti-poliovirus (Anti-polio) Types 1, 2 and 3.</title>
        <time_frame>At Month 0 and Month 5</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>12/2015</posting_date>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Concentrations of Anti-PT Antibodies.</title>
        <time_frame>At Month 0 and Month 5</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>12/2015</posting_date>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Concentrations of Anti-FHA Antibodies.</title>
        <time_frame>At Month 0 and Month 5</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>12/2015</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentrations for Anti-D and Anti-T Antibodies.</title>
        <description>Concentrations were expressed as geometric mean concentrations (GMCs). The seroprotection cut-off of the assay was 0.1 IU/mL.</description>
        <time_frame>At Month 0 and Month 5</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, which included all evaluable subjects who received one dose of either study vaccine according to their random assignment, for whom administration site of study vaccine was known and for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix-IPV+Hib Group</title>
            <description>Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™-IPV+Hib at 2, 4 and 6 months of age, 3 doses of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™-IPV+Hib was administered intramuscularly in the right thigh, the Synflorix™ vaccine was administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix IPV Group</title>
            <description>Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™ IPV and Hiberix™ co-administered at separate injection sites at 2, 4 and 6 months of age, 3 dose of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™ IPV was administered intramuscularly in the right thigh, the Synflorix™ and Hiberix™ vaccines were administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="213"/>
                  <measurement group_id="O2" value="217"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Concentrations for Anti-D and Anti-T Antibodies.</title>
            <description>Concentrations were expressed as geometric mean concentrations (GMCs). The seroprotection cut-off of the assay was 0.1 IU/mL.</description>
            <units>IU/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Anti-D at Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.058" lower_limit="0.055" upper_limit="0.061"/>
                  <measurement group_id="O2" value="0.060" lower_limit="0.056" upper_limit="0.064"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-D at Month 5</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8.096" lower_limit="7.520" upper_limit="8.717"/>
                  <measurement group_id="O2" value="8.692" lower_limit="8.125" upper_limit="9.298"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-T at Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.081" lower_limit="0.072" upper_limit="0.090"/>
                  <measurement group_id="O2" value="0.091" lower_limit="0.080" upper_limit="0.103"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-T at Month 5</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10.259" lower_limit="9.654" upper_limit="10.902"/>
                  <measurement group_id="O2" value="12.421" lower_limit="11.599" upper_limit="13.301"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentrations of Anti-PRN Antibodies.</title>
        <description>Concentrations were expressed as geometric mean concentrations (GMCs). The seropositivity cut-off of the assay was 5 EL.U/mL.</description>
        <time_frame>At Month 0 and Month 5</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, which included all evaluable subjects who received one dose of either study vaccine according to their random assignment, for whom administration site of study vaccine was known and for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix-IPV+Hib Group</title>
            <description>Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™-IPV+Hib at 2, 4 and 6 months of age, 3 doses of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™-IPV+Hib was administered intramuscularly in the right thigh, the Synflorix™ vaccine was administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix IPV Group</title>
            <description>Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™ IPV and Hiberix™ co-administered at separate injection sites at 2, 4 and 6 months of age, 3 dose of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™ IPV was administered intramuscularly in the right thigh, the Synflorix™ and Hiberix™ vaccines were administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="213"/>
                  <measurement group_id="O2" value="217"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Concentrations of Anti-PRN Antibodies.</title>
            <description>Concentrations were expressed as geometric mean concentrations (GMCs). The seropositivity cut-off of the assay was 5 EL.U/mL.</description>
            <units>EL.U/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Anti-PRN at Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.9" lower_limit="2.7" upper_limit="3.0"/>
                  <measurement group_id="O2" value="3.1" lower_limit="2.8" upper_limit="3.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-PRN at Month 5</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="125.8" lower_limit="116.0" upper_limit="136.5"/>
                  <measurement group_id="O2" value="133.4" lower_limit="123.0" upper_limit="144.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentrations of Anti-PRP Antibodies.</title>
        <description>Concentrations were expressed as geometric mean concentrations (GMCs). The seroprotection cut-off of the assay was 0.15 µg/mL.</description>
        <time_frame>At Month 0 and Month 5</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, which included all evaluable subjects who received one dose of either study vaccine according to their random assignment, for whom administration site of study vaccine was known and for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix-IPV+Hib Group</title>
            <description>Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™-IPV+Hib at 2, 4 and 6 months of age, 3 doses of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™-IPV+Hib was administered intramuscularly in the right thigh, the Synflorix™ vaccine was administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix IPV Group</title>
            <description>Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™ IPV and Hiberix™ co-administered at separate injection sites at 2, 4 and 6 months of age, 3 dose of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™ IPV was administered intramuscularly in the right thigh, the Synflorix™ and Hiberix™ vaccines were administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="213"/>
                  <measurement group_id="O2" value="217"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Concentrations of Anti-PRP Antibodies.</title>
            <description>Concentrations were expressed as geometric mean concentrations (GMCs). The seroprotection cut-off of the assay was 0.15 µg/mL.</description>
            <units>µg/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Anti-PRP at Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.165" lower_limit="0.143" upper_limit="0.191"/>
                  <measurement group_id="O2" value="0.219" lower_limit="0.184" upper_limit="0.260"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-PRP at Month 5</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8.456" lower_limit="7.283" upper_limit="9.819"/>
                  <measurement group_id="O2" value="18.700" lower_limit="16.353" upper_limit="21.384"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With a Vaccine Response.</title>
        <description>Vaccine response was defined as antibody concentration ≥ 5 EL.U/mL at post vaccination, for initially seronegative subjects, and at least maintenance of antibody concentration from pre to post-vaccination (i.e. antibody concentration at post vaccination ≥ 1 fold the pre-vaccination antibody concentration), for initially seropositive subjects.</description>
        <time_frame>At Month 5</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, which included all evaluable subjects who received one dose of either study vaccine according to their random assignment, for whom administration site of study vaccine was known and for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix-IPV+Hib Group</title>
            <description>Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™-IPV+Hib at 2, 4 and 6 months of age, 3 doses of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™-IPV+Hib was administered intramuscularly in the right thigh, the Synflorix™ vaccine was administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix IPV Group</title>
            <description>Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™ IPV and Hiberix™ co-administered at separate injection sites at 2, 4 and 6 months of age, 3 dose of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™ IPV was administered intramuscularly in the right thigh, the Synflorix™ and Hiberix™ vaccines were administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="213"/>
                  <measurement group_id="O2" value="217"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With a Vaccine Response.</title>
            <description>Vaccine response was defined as antibody concentration ≥ 5 EL.U/mL at post vaccination, for initially seronegative subjects, and at least maintenance of antibody concentration from pre to post-vaccination (i.e. antibody concentration at post vaccination ≥ 1 fold the pre-vaccination antibody concentration), for initially seropositive subjects.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="213"/>
                  <measurement group_id="O2" value="216"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentrations for Anti-polio Types 1, 2 and 3.</title>
        <time_frame>At Month 0 and Month 5</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>12/2015</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seropositive Subjects for Anti-PT Antibodies.</title>
        <time_frame>At Month 0 and Month 5</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>12/2015</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seropositive Subjects for Anti-FHA Antibodies.</title>
        <time_frame>At Month 0 and Month 5</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>12/2015</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>SAE(s): during the entire study period (Month 0 to Month 5 ½); Solicited local/general symptoms: during the 4-day (Days 0-3) follow-up period after any vaccination; Unsolicited AE(s): during the 31-day (Days 0-30) follow-up period after any vaccination.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Infanrix-IPV+Hib Group</title>
          <description>Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™-IPV+Hib at 2, 4 and 6 months of age, 3 doses of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™-IPV+Hib was administered intramuscularly in the right thigh, the Synflorix™ vaccine was administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.</description>
        </group>
        <group group_id="E2">
          <title>Infanrix IPV Group</title>
          <description>Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™ IPV and Hiberix™ co-administered at separate injection sites at 2, 4 and 6 months of age, 3 dose of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™ IPV was administered intramuscularly in the right thigh, the Synflorix™ and Hiberix™ vaccines were administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Vesicoureteric reflux</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="181" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="182" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="143" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="146" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="177" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="167" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="130" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="121" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="153" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="147" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Irritability/Fussiness</sub_title>
                <counts group_id="E1" subjects_affected="181" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="182" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <counts group_id="E1" subjects_affected="120" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="103" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Temperature (Tympanic)</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
